QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Summary

This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period. Subjects will receive QL1706 5mg/kg iv every 3 weeks until disease progression or intolerance. Efficacy should be evaluated and safety will be monitored throughout the study.

Timeline

Start

2025-09-28

Primary completion

2027-05-01

Completion

2028-05-01

Drugs

Indications